Press Releases

NASHVILLE, Tenn. , May 14, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced first quarter 2019 financial results with net revenues of $11.9 million

NASHVILLE, Tenn. , May 7, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2019 financial results after the market closes on Tuesday, May 14 , 2019.  A conference call and live Internet webcast will be held on Tuesday, May 14 ,

- Review follows rapid growth in product portfolio - Will also include review of expanded group of international partners NASHVILLE, Tenn. , March 29, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced that it has commenced a

- Acquired Vibativ® from Theravance Biopharma - Closed largest product transaction in Company's history - Acquisition funded by $20 million credit line expansion NASHVILLE, Tenn. , Feb. 26, 2019 /PRNewswire/ --   Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company

NASHVILLE, Tenn. , Feb. 19, 2019 /PRNewswire/ --   Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2018 financial results after the market closes on Tuesday, February 26 , 2019.  A conference call and live Internet webcast will be held

NASHVILLE, Tenn. , Nov. 13, 2018 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2018 financial results and Company update.

NASHVILLE, Tenn. , Nov. 7, 2018 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2018 financial results after the market closes on Tuesday, November 13 , 2018.  A conference call and live Internet webcast will be held on Tuesday,

FDA approved injectable anti-infective with life-saving potential NASHVILLE, Tenn. , Nov. 6, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.   (NASDAQ: CPIX) announced today that it has entered into a definitive agreement to acquire VIBATIV ® from Theravance Biopharma .

NASHVILLE, Tenn. (October 29, 2018) – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, today announced the publication of a study, with supporting data, concluding that preemptive anesthesia with IV ibuprofen is superior when compared to IV acetaminophen in

New study data supports the use of Caldolor® in reducing pain and reliance on opioids compared to ketorolac. NASHVILLE, Tenn. (October 22, 2018) – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of a study in patients undergoing arthroscopic knee surgery that reveals